Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2/seipin-deficient mice

Endocrinology (United States)

Volumn 155, Issue 11, 2014, Pages 4215-4225

  Chen, Weiqin ^a   Zhou, Hongyi ^a   Saha, Pradip ^b   Li, Luge ^b   Chan, Lawrence ^b,c,d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Department of Medicine   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d CHI ST LUKE S HEALTH BAYLOR ST LUKE S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BSCL2 PROTEIN; CERAMIDE; DIACYLGLYCEROL; GLUCOSE; INSULIN; LIPID; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; BSCL2 PROTEIN, MOUSE; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGENITAL GENERALIZED LIPODYSTROPHY; CONTROLLED STUDY; DIET RESTRICTION; FATTY ACID OXIDATION; FATTY LIVER; GLUCOSE CLAMP TECHNIQUE; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; MALE; MOLECULAR DYNAMICS; MORPHOLOGICAL ADAPTATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM;

ANIMALS; DISEASE MODELS, ANIMAL; FASTING; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; INSULIN RESISTANCE; LIPODYSTROPHY, CONGENITAL GENERALIZED; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION;

EID: 84908052440     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1292     Document Type: Article

References (39)

1. Berardinelli W. Anundiagnosed endocrinometabolic syndrome: Report of 2 cases. J Clin Endocrinol Metab. 1954;14:193-204.
2. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr. 1996;Suppl 413:2-28.
3. Garg A. Clinical review#: Lipodystrophies: Genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313-3325.
4. Gomes KB, Pardini VC, Fernandes AP. Clinical and molecular aspects of Berardinelli-Seip Congenital Lipodystrophy (BSCL). Clin Chim Acta. 2009;402:1-6.
5. Magré J, Delépine M, Khallouf E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28:365-370.
6. Cui X, Wang Y, Tang Y, et al. Seipin ablation in mice results in severe generalized lipodystrophy. Hum Mol Genet. 2011;20:3022-3030.
7. Chen W, Chang B, Saha P, et al. Berardinelli-seip congenital lipodystrophy 2/seipin is a cell-autonomous regulator of lipolysis essential for adipocyte differentiation. Mol Cell Biol. 2012;32:1099-1111.
8. Prieur X, Dollet L, Takahashi M et al. Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice. Diabetologia. 2013;56:1813-1825.
9. Moitra J, Mason MM, Olive M, et al. Life without white fat: A transgenic mouse. Genes Dev. 1998;12:3168-3181.
10. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy. Genes Dev. 1998;12:3182-3194.
11. Cortés VA, Curtis DE, Sukumaran S, et al. Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell metab. 2009;9:165-176.
12. Fei W, Li H, Shui G, et al. Molecular characterization of seipin and its mutants: Implications for seipin in triacylglycerol synthesis. J Lipid Res. 2011;52:2136-2147.
13. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem. 2000;275:8456-8460.
14. Saha PK, Kojima H, Martinez-Botas J, Sunehag AL, Chan L. Metabolic adaptations in the absence of perilipin: Increased beta-oxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in perili-pin- null mice. J Biol Chem. 2004;279:35150-35158.
15. Lord CC, Betters JL, Ivanova PT, et al. CGI-58/ABHD5-derived signaling lipids regulate systemic inflammation and insulin action. Diabetes. 2012;61:355-363.
16. Qu X, Seale JP, Donnelly R. Tissue and isoform-selective activation of protein kinase C in insulin-resistant obese Zucker rats - effects of feeding. J Endocrinol. 1999;162:207-214.
17. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
18. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345-32353.
19. Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM, Bielawska A. Sphingolipid analysis by high performance liquid chromatographytandem mass spectrometry (HPLC-MS/MS). Adv Exp Med Biol. 2010;688:46-59.
20. Dasgupta S, Hogan EL. Chromatographic resolution and quantitative assay of CNS tissue sphingoids and sphingolipids. J Lipid Res. 2001;42:301-308.
21. Chen W, Chang B, Wu X, Li L, Sleeman M, Chan L. Inactivation of Plin4 downregulates Plin5 and reduces cardiac lipid accumulation in mice. Am J Physiol Endocrinol Metab. 2013;304:E770-779.
22. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
23. Erion DM, Shulman GI. Diacylglycerol-mediated insulin resistance. Nature medicine. 2010;16:400-402.
24. Samuel VT, Shulman GI. Mechanisms for insulin resistance: Common threads and missing links. Cell. 2012;148:852-871.
25. Samuel VT, Liu ZX, Wang A, et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J Clin Invest. 2007;117:739-745.
26. Chen Z, Norris JY, Finck BN. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) stimulates VLDL assembly through activation of cell death-inducing DFFA-like effector B (CideB). J Biol Chem. 2010;285:25996-26004.
27. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: From feast to famine. Genes Dev. 2012;26:312-324.
28. Chen W, Yechoor VK, Chang BH, Li MV, March KL, Chan L. The human lipodystrophy gene product Berardinelli-Seip congenital lipodystrophy 2/seipin plays a key role in adipocyte differentiation. Endocrinology. 2009;150:4552-4561.
29. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes. 2006;55:390-397.
30. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. 2008;295:E1323-1332.
31. Ayala JE, Samuel VT, Morton GJ, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010;3:525-534.
32. Tschöp MH, Speakman JR, Arch JR, et al. A guide to analysis of mouse energy metabolism. Nat Methods. 2012;9:57-63.
33. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: Unraveling the mechanism. Lancet. 2010;375:2267-2277.
34. Cui X, Wang Y, Meng L, et al. Overexpression of a short human seipin/BSCL2 isoform in mouse adipose tissue results in mild lipodystrophy. Am J Physiol Endocrinol Metab. 2012;302:E705-713.
35. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85-96.
36. Hirashima Y, Tsuruzoe K, Kodama S, et al. Insulin down-regulates insulin receptor substrate-2 expression through the phosphatidylinositol 3-kinase/Akt pathway. J Endocrinol. 2003;179:253-266.
37. Vila-Brau A, De Sousa-Coelho AL, Mayordomo C, Haro D, Marrero PF. Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line. J Biol Chem. 2011;286:20423-20430.
38. Melvin RG, Andrews MT. Torpor induction in mammals: Recent discoveries fueling new ideas. Trends Endocrinol Metab. 2009;20:490-498.
39. Brown MS, Goldstein JL. Selective versus total insulin resistance: A pathogenic paradox. Cell Metabol. 2008;7:95-96.